Cardiff Oncology, Inc. (CRDF) vs VAXART, INC. (VXRT)
Cardiff Oncology, Inc. and VAXART, INC. are both Biotechnology companies. Cardiff Oncology, Inc. and VAXART, INC. are of similar size ($99.6M and $92.4M). Cardiff Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; VAXART, INC. trades at 2.8×. VAXART, INC. grew revenue faster over the last twelve months: 201.1% against −6.79%. VAXART, INC. has the higher net margin (15.9% vs −7,889.0%) and the higher return on invested capital (134.6% vs 0.00%). Across the 16 metrics below, VAXART, INC. leads on 15 and Cardiff Oncology, Inc. on 1.
Valuation
Profitability
| Metric | CRDF | VXRT | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (8,320.08%) | 16.30% | 0.00% |
| Net margin | (7,888.98%) | 15.88% | 0.00% |
| Free cash flow margin | (8,059.45%) | 13.74% | 0.00% |
| Return on equity | (94.14%) | 66.97% | (57.72%) |
| Return on assets | (70.89%) | 23.44% | (49.22%) |
| Return on invested capital | 0.00% | 134.59% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack